Scinovex
article Open AccessTop 1% cited

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

Diabetologia · 2009 · Vol. 52(9) · pp. 1766–1777
C. J. CurrieC PooleE.A.M. Gale
Metabolism, Diabetes, and CancerPancreatic and Hepatic Oncology ResearchCancer-related Molecular PathwaysMetforminMedicineInsulin glargineInsulinInternal medicineSulfonylureaType 2 diabetesEndocrinologyDiabetes mellitusCancer

MeSH terms

Administration, OralAdultAgedAged, 80 and overBlood PressureDiabetes Mellitus, Type 2Family PracticeFemaleUnited KingdomGlycated HemoglobinHumansHypoglycemic AgentsInsulinMaleMetformin

Funding

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi
  • Novo Nordisk
Citations
1,114
FWCI
52.97
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
References
Diabetes mellitus and risk of breast cancer: A meta‐analysis
International Journal of Cancer · 2007 · 865 citations
Genetics and biology of pancreatic ductal adenocarcinoma
Genes & Development · 2006 · 1,568 citations
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
New England Journal of Medicine · 2008 · 7,704 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.